Abstracts tagged "Biologics"

Abstract Number: 2452 • 2018 ACR/ARHP Annual Meeting
Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients
Su-Jin Moon¹, Min Jung Kim², Sun Kyung Lee², So Hee Oh², Hyoun-Ah Kim³ and Kichul Shin⁴, ¹Bucheon St. Mary's Hospital, Division of rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Herpes zoster (HZ) infection is not uncommon in rheumatoid arthritis (RA) patients, especially in those treated with biologic or targeted synthetic (bts) disease-modifying antirheumatic…
Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…
Abstract Number: 564 • 2018 ACR/ARHP Annual Meeting
Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)
Katie Tuckwell¹, Cem Gabay², Thierry Sornasse¹, Ruediger Laubender³, Jianmei Wang⁴ and Michael Townsend¹, ¹Genentech, Inc., South San Francisco, CA, ²University Hospitals of Geneva, Geneva, Switzerland, ³Roche Diagnostics, Penzberg, Germany, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: The biomarkers CXCL13 and sICAM1 have been associated with outcomes in patients with RA treated with TCZ. This study evaluated the association of CXCL13…
Abstract Number: 1489 • 2018 ACR/ARHP Annual Meeting
“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment
Takayoshi Owada¹, Kazuhiro Kurasawa¹, Yuta Takamura¹, Tomoyuki Miyao¹, Ayae Tanaka¹, Ryutaro Yamazaki², Satoko Arai¹, Reika Maezawa¹ and Masafumi Arima³, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan, ³Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan
Background/Purpose: Relative change of serum RF titer has been reported to correlate with those of RA disease activity. However, it is debatable whether serum RF…
Abstract Number: 2453 • 2018 ACR/ARHP Annual Meeting
Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
Susan M. Goodman¹, Bo Shopsin², Allina A. Nocon¹, Andy O. Miller³, Michael W. Henry³, Sarah E. Grond¹, Elianna Kaplowitz¹, Thomas P. Sculco⁴, Linda A. Russell³, Laura T. Donlin⁵, Mark P. Figgie⁴ and Peter K. Sculco⁴, ¹Hospital for Special Surgery, New York, NY, ²Medicine and Microbiology, New York University School of Medicine, New York, NY, ³Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection than patients with osteoarthritis (OA). Disease modifying therapy is widely used…
Abstract Number: 2608 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
Iain B. McInnes¹, Alan J. Kivitz², Peter Nash³, Proton Rahman⁴, Juergen Rech⁵, Bruce Kirkham⁶, Sandra V. Navarra⁷, Kevin Ding⁸, Emma Ilsley⁹ and Luminita Pricop¹⁰, ¹University of Glasgow, Glasgow, United Kingdom, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Queensland, Brisbane, Australia, ⁴Memorial University, St John's, NF, Canada, ⁵University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, provided sustained improvement in the signs and symptoms of active psoriatic arthritis…
Abstract Number: 11L • 2017 ACR/ARHP Annual Meeting
Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
Lene Dreyer¹, René Cordtz², Inger Marie J. Hansen³, Lars Erik Kristensen⁴, Merete Lund Hetland⁵ and Lene Mellemkjær⁶, ¹Center for Rheumatology and Spine Diseases, Gentofte University Hospital,Rigshospitalet, Hellerup, Denmark, ²Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Hellerup, Denmark, ³Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ⁴The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁵DANBIO, Glostrup Hospital.On behalf of all Depts of Rheumatology in Denmark.Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ⁶Danish Cancer Society Research Center, Copenhagen, Denmark, Copenhagen, Egypt

Background/Purpose: The safety of treatment with biological DMARDs (bDMARDs) has been carefully studied for the past 15 years, however, it is still largely unknown whether…
Abstract Number: 546 • 2017 ACR/ARHP Annual Meeting
Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis
Ming Zhao¹, Harlan Sayles², James R. O'Dell¹ and Kaleb Michaud^2,3, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) have been widely used in patients who failed conventional DMARDs in the treatment of rheumatoid arthritis (RA). While most…
Abstract Number: 1001 • 2017 ACR/ARHP Annual Meeting
Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy
Theresa Hunter¹, Krista Schroeder², Sarah Al Sawah² and David Sandoval Calderon², ¹Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The primary goals of treating Ankylosing Spondylitis (AS) patients are to maximize long-term health-related quality of life through control of symptoms and inflammation, prevention…
Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Vibeke Strand¹, Rita Ganguly², Nan Li³, Prasheen Agarwal³, Shihong Sheng³, Kaiyin Fei³, Kelly McQuarrie³ and Sharon Popik³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²GlaxoSmithKline, Collegeville, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases. Effects of sirukumab on RA symptoms…
Abstract Number: 2445 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab Biosimilar, CT-P10, after a Single Switch from Innovator Rituximabs in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 72 Weeks
Seung-Cheol Shim¹, Ljubinka Bozic Majstorovic², Alfredo Berrocal Kasay³, Elias Chalouhi El-Khouri⁴, Fedra Irazoque-Palazuelos⁵, Francisco Cons Molina⁶, Francisco G. Medina-Rodriguez⁷, Pedro Miranda⁸, Pavel Shesternya⁹, Jose Chavez Corrales¹⁰, Piotr Wiland¹¹, Slawomir Jeka¹², Olena Garmish¹³, Pawel Hrycaj¹⁴, Natalia Fomina¹⁵, Won Park¹⁶, Chang-Hee Suh¹⁷, Sang-Joon Lee¹⁸, Sung Young Lee¹⁹ and Dae-Hyun Yoo²⁰, ¹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ²Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, ³ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, ⁴Clinica Internacional, Lima, Peru, ⁵Centro de Invstigacion y Tratamiento Reumatologico S.C, Mexico City, Mexico, ⁶Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁷Rheumatology, LaSalle University, Mexico City, Mexico, ⁸Centro De Estudios Reumatológicos, Santiago, Chile, ⁹Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹⁰Clinica San Borja, Lima, Peru, ¹¹Department and Clinic of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ¹²2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ¹³Institute of Cardiology named by M.D. Strazhesko NAMS of Ukraine, Kyiv, Ukraine, ¹⁴Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ¹⁵Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation, ¹⁶Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ¹⁷Ajou University School of Medicine, Suwon, Korea, Republic of (South), ¹⁸CELLTRION, Inc., Incheon, Korea, Republic of (South), ¹⁹Clinical Planning Department, CELLTRION, Inc., Incheon, Korea, Republic of (South), ²⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Similarity of pharmacokinetic, efficacy and safety between CT-P10 and reference rituximab (RTX) were shown in the phase 3 randomized controlled trial (NCT02149121) up to…
Abstract Number: 2779 • 2017 ACR/ARHP Annual Meeting
The Patient Perspective on Bdmard Dose Reduction: A Mixed Methods Study
L.M. Verhoef¹, E.M.H. Selten¹, J.E. Vriezekolk¹, A.J.L. de Jong², F.H.J. van den Hoogen^1,3, A.A. Den Broeder^1,3 and M.E.J.L. Hulscher⁴, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ³Rheumatology, Radboud university medical centre, Nijmegen, Netherlands, ⁴Radboud Institute for Health Sciences, IQ healthcare, Radboud university medical centre, Nijmegen, Netherlands
Background/Purpose: biological DMARDs (bDMARDs) are effective in the treatment of RA, but are also associated with side-effects and high costs. Dose reduction of bDMARDs, after…
Abstract Number: 550 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
Shalini Mohan¹, Margaret Michalska², Jeffrey Yourish², Jinglan Pei², Sara Gale¹, Christine Birchwood² and Erhan Berber², ¹Genentech, South San Francisco, CA, ²Genentech, Inc., South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody targeted against the interleukin-6 receptor that was approved to treat rheumatoid arthritis (RA) in the EU…
Abstract Number: 1040 • 2017 ACR/ARHP Annual Meeting
Perceptions of US Community Rheumatologists on Biosimilars
Janna Radtchenko, Yolaine Smith, Jonathan Kish and Bruce Feinberg, Specialty Solutions, Cardinal Health, Dallas, TX
Background/Purpose: Biosimilars contain a highly similar version of the active substance of an already approved biologic or “reference product.”1 Regulatory agencies mandate that safety, efficacy,…
Abstract Number: 1523 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Jürgen Braun¹, Joachim Sieper², Robert B.M. Landewé³, Xenofon Baraliakos¹, Corinne Miceli-Richard⁴, Ruvie Martin⁵, Brian Porter⁵, Kunal Gandhi⁵ and Désirée van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, Hôpital Bicêtre, Paris, France, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα…

« Previous Page
1
…
6
7
8
9
10
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].